Date Added: 01/02/2017

Date Updated: 20/09/2017

EPICUP: epigenetic profiling to classify cancer of unknown primary

Specialties: Oncology & radiotherapy

Technology Type: Diagnostics

Stage of development: Nearly established

Stage of EAA: Identified

Description, patients and keywords:

Description of the technology: Epigenetic technique that allows the classification of a group of cancers defined by the presence of metastatic disease with no identified primary tumour at presentation. The Epicub test is based on DNA methylation profiles (microarray DNA methylation signatures); it identifies the specific methylation profile of the tumour, assigning a primary origin to the unknown tumour sample. According to the company, Ferrer Hospital, Epicub has more than 90% coverage of the most frequent solid tumours and offers a very high overall accuracy. The company reports that it can be run in fresh frozen (FF) or formalin fixed and paraffin embedded (FFPE) procedures.

Patient indication: Patients diagnosed with cancer of unknown primary, CUP, (without the detection of the origin of the primary tumour with the usual techniques).



This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.